Brendan Luu

CIK: 0001842369

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (18.2%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (45.5%)

Compensation grants

Other (G, F, J, C, D, …)4 (36.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ENTA

ENANTA PHARMACEUTICALS INC

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
1.6K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Award(A)
Direct
5K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2026
Tax Payment(F)
Direct
3.3K shares at avg. $14.25$46K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 5, 2025
Sale(S)
Direct
1.4K shares at avg. $14.23$20K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 1, 2025
Tax Payment(F)
Direct
498 shares at avg. $14.12$7K
ENTA
ENANTA PHARMACEUTICALS INC
Nov 25, 2025
Award(A)
Stock Option (right to buy)
Direct
90K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2025
Award(A)
Direct
7.5K shares-
ENTA
ENANTA PHARMACEUTICALS INC
Feb 12, 2025
Tax Payment(F)
Direct
3.3K shares at avg. $5.59$19K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 6, 2024
Sale(S)
Direct
2.3K shares at avg. $8.06$18K
ENTA
ENANTA PHARMACEUTICALS INC
Dec 1, 2024
Tax Payment(F)
Direct
753 shares at avg. $8.60$6K
ENTA
ENANTA PHARMACEUTICALS INC
Nov 27, 2024
Award(A)
Stock Option (right to buy)
Direct
75K shares-

		Type	Shares	Price		Ownership
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	1,575	-	$0	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	4,987	-	$0	Direct
Feb 12, 2026	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	3,257	$14.25	$46,412	Direct
Dec 5, 2025	ENTA ENANTA PHARMACEUTICALS INC	Sale(S)	1,394	$14.23	$19,837	Direct
Dec 1, 2025	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	498	$14.12	$7,032	Direct
Nov 25, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	90,000	-	-	Direct
Feb 12, 2025	ENTA ENANTA PHARMACEUTICALS INC	Award(A)	7,500	-	-	Direct
Feb 12, 2025	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	3,326	$5.59	$18,592	Direct
Dec 6, 2024	ENTA ENANTA PHARMACEUTICALS INC	Sale(S)	2,283	$8.06	$18,401	Direct
Dec 1, 2024	ENTA ENANTA PHARMACEUTICALS INC	Tax Payment(F)	753	$8.60	$6,476	Direct
Nov 27, 2024	ENTA ENANTA PHARMACEUTICALS INC	Award(A) Stock Option (right to buy)	75,000	-	-	Direct

1-11 of 11 transactions

About Luu Brendan

Luu Brendan (SEC CIK 0001842369) files insider reports with the SEC as Chief Business Officer of ENANTA PHARMACEUTICALS INC (ENTA).

Signal8 holds 8 ownership filings by Luu Brendan, all Form 4s, filed between Nov 27, 2024 and Feb 13, 2026. Those filings report 11 transactions, from Nov 27, 2024 to Feb 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Luu Brendan's filings is in WATERTOWN, MA.

Recent filings by Luu Brendan

Feb 12, 2026: Grants or awards of ENTA shares (2 lines, Form 4, code A).
Feb 12, 2026: Tax withholding of ENTA shares (Form 4, code F).
Dec 5, 2025: Open-market sale of ENTA shares (Form 4, code S).
Dec 1, 2025: Tax withholding of ENTA shares (Form 4, code F).
Nov 25, 2025: Grant or award of ENTA derivative securities (Form 4, code A).

Other insiders filing for ENANTA PHARMACEUTICALS INC (ENTA)

Rottinghaus Scott T., Chief Medical Officer
Vance Terry, Director
Russell Lesley, Director
Peterson Kristine, Director
Hata Yujiro S, Director
FOLETTA MARK G, Director

How to read Form 4 transaction codes